Artimplant presents data on Artelon® for cartilage repair in the knee

A laboratory study (in vitro) and an animal study, which are currently being presented at the 9th World Congress of the International Cartilage Repair Society, demonstrate that Artelon® functions as a scaffold for cells in conjunction with cartilage repair.

Both locally recruited cells obtained through bleeding as well as in vitro cultured human chondrocytes, which are currently in clinical use, have been studied. The results show that the newly formed tissue is improved with the use of Artelon®.

Professor Lars Peterson, Sahlgrenska University Hospital, has led the animal study:

“There is a considerable clinical need to improve the outcome of cartilage repair. The studies show the potential that exists in the Artelon® material as a scaffold and that it contributes to tissue healing.”

Dr. Sebastian Concaro, orthopedic surgeon and also involved in the animal study:

“The results are very promising and show that the material is well tolerated in the joint and provides good cartilage repair.”

Dr. Katrin Gisselfält, VP Research & Development at Artimplant:

“The results offer good conditions and proof of concept for Artimplant to develop additional products for the treatment of cartilage injuries.”

For further information, please contact: Hans Rosén, CEO, phone 46 (0)31-746 56 00, 46 (0)708 58 34 70, (

Lars-Johan Cederbrant, CFO, phone 46 (0)31-746 56 54, 46 (0)703 01 68 54, (

Further information is available at ( To subscribe to future press releases please go to (


Artimplant’s mission is to restore the health of patients by offering medical professionals degradable implants that help the body to heal. Artimplant is a medical technology company that restores health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products are made from Artelon®, a biomaterial developed by the Company. Artimplant produces implants for the treatment of osteoarthritis and the reinforcement of weakened soft tissue. The Company’s products are sold through licensees and own sales under the Artimplant brand take place through agents and distributors. Artimplant is a public company listed on the NASDAQ OMX Stockholm Exchange in the Small Cap segment and in the Healthcare sector.

Forward-looking statements

This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company’s business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company’s filings.
This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on September 29 2010 at 8:45am (CET).

This information was brought to you by Waymaker:

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button